Evidence map›Paper›PMID 33888882›Full record

ArticleNature microbiology2021

Publisher Correction: Gut-inhabiting Clostridia build human GPCR ligands by conjugating neurotransmitters with diet- and human-derived fatty acids.

Fang-Yuan Chang, Piro Siuti, Stephane Laurent, Thomas Williams, Emerson Glassey, Andreas W Sailer, David Benjamin Gordon, Horst Hemmerle, Christopher A Voigt

Abstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Fang-Yuan ChangSynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5819-6454
Piro SiutiSynthetic Biology Group, Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Stephane LaurentDisease Area X, Novartis Institutes for BioMedical Research, Basel, Switzerland.
Thomas WilliamsThe Foundry, Broad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3288-9513
Emerson GlasseySynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
Andreas W SailerDisease Area X, Novartis Institutes for BioMedical Research, Basel, Switzerland.ORCID http://orcid.org/0000-0002-9015-7946
David Benjamin GordonSynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-0619-7791
Horst HemmerleSynthetic Biology Group, Global Discovery Chemistry, Novartis Institutes for BioMedical Research, Cambridge, MA, USA.
Christopher A VoigtSynthetic Biology Center, Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. cavoigt@gmail.com.ORCID http://orcid.org/0000-0003-0844-4776

Funding

United States Department of Defense | Defense Advanced Research Projects Agency (DARPA) HR0011-15-C-0084
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID33888882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.